Company Overview: Novogen Limited

Industry News

30 Sep

Novogen Applies for Long-term Options Listing

SYDNEY, Sept. 30, 2015 /PRNewswire/ — US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today announced that it will apply for the listing of the Long-Term Options on ASX and anticipates that this request will be granted within the next week. An Appendix 3B has been released...

Read more

31 Aug

Novogen Announces The Outcome Of A Comprehensive Science Review

– Novogen will focus the development programs for each of our three lead candidates to achieve the earliest possible initiation of clinical studies. We affirm our goal to have two products enter clinical development in 2016 – Specific indications, formulations and routes of administration have been confirmed for each...

Read more

22 Jul

Novogen Appoints Iain Ross as Acting CEO and Re-appoints Him to the Board

Novogen Limited (ASX:NRT; NASDAQ: NVGN), a US-Australian drug development company, today announced the appointment to the Board of Iain Ross, an experienced multi-national pharmaceutical and biotechnology executive. Mr Ross, a former director of Novogen Limited will re-join the Board with immediate effect and take on the role of Acting Chief...

Read more

16 Jul

Anisina Receives Orphan Drug Designation from FDA for Neuroblastoma.

US-Australian drug discovery company, Novogen Limited, today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblastoma. Orphan Drug Designation encourages the development of experimental drugs for clinical indications that do...

Read more

12 Jun

Novogen to Present at Bio International Convention Philadelphia 2015

US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced today that Novogen Group CEO, Graham Kelly, will be presenting at the Bio International Convention 2015 (BIO) being held at the Pennsylvania Convention Centre, 1101 Arch St, Philadelphia, PA 19107. Details of the Novogen presentation are as follows: Presentation...

Read more

4 Jun

Studies Confirm TRXE-009 Crosses the Blood-brain Barrier

— Crosses the BBB in a proprietary lipid construct — Potential to treat both primary and secondary brain cancers US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) confirms that a lipid formulation of TRXE-009 dosed intravenously to animals was able to deliver therapeutic concentrations of TRXE-009 to brain tissue....

Read more

18 May

Novogen to Present at Hong Kong Investor Conference

US-Australian drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ: NVGN), announced today that company CEO, Dr Graham Kelly, will be a presenting company at Asia Biotech Invest 2015May 20-21. The Novogen presentation is at 10.00 am May 20 at the Sheraton Hotel and Towers, Hong Kong. The event...

Read more

29 Apr

Novogen Completes the Private Placement of Equity

US-Australian drug discovery company, Novogen Limited (NRT: ASX; NVGN: NASDAQ) (Novogen or Company), announced today that it has completed the placement to US institutional investors of 51,750,000 ordinary shares, raising a total of $15,525,000 (before costs), as previously announced to the market on 21 April 2015. Subject to Shareholder...

Read more

27 Apr

Novogen Posts Details on Rights Issue Offering for Shareholders

US-Australian drug discovery company, Novogen Limited (NRT: ASX; NVGN: NASDAQ) (Company), announced last week that it lodged a prospectus with ASIC on 23 April 2015 relating to its pro rata non-renounceable rights issue (Offering). The prospectus has been posted on its website and notices to shareholders and optionholders have...

Read more

20 Apr

Cantrixil Highly Successful in Preventing Growth of Chemo-Resistant Ovarian Cancer

— Animal model highly representative of late-stage ovarian cancer in women — Model proven resistant to all previous experimental and standard therapies — Cantrixil providing potent anti-cancer effect US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; NASDAQ:NVGN), its subsidiary, CanTx, Inc, and Yale University today disclosed key pre-clinical data on...

Read more

Page 1 of 212

Enter your email address to receive notifications of new posts by email.

Latest Tweets


Follow this blog

Get every new post delivered right to your inbox.

Email address